Drug Price Trends for NDC 60505-6188

Average Pharmacy Cost for 60505-6188

Drug Name	NDC	Price/Unit ($)	Unit	Date
TERIPARATIDE 560 MCG/2.24 ML PEN	60505-6188-00	595.53757	ML	2026-03-18
TERIPARATIDE 560 MCG/2.24 ML PEN	60505-6188-00	624.89100	ML	2026-02-18
TERIPARATIDE 560 MCG/2.24 ML PEN	60505-6188-00	674.44068	ML	2026-01-21
TERIPARATIDE 560 MCG/2.24 ML PEN	60505-6188-00	673.24834	ML	2025-12-17
TERIPARATIDE 560 MCG/2.24 ML PEN	60505-6188-00	687.25084	ML	2025-11-19
TERIPARATIDE 560 MCG/2.24 ML PEN	60505-6188-00	670.52875	ML	2025-10-22
TERIPARATIDE 560 MCG/2.24 ML PEN	60505-6188-00	846.07491	ML	2025-04-02

Best Wholesale Price for NDC 60505-6188

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
TERIPARATIDE RECOMBINANT 250MCG/ML (600MCG) I	Golden State Medical Supply, Inc.	60505-6188-00	2.4ML	1796.00	748.33333	2024-05-15 - 2028-06-14	FSS

NDC 60505-6188: Market Trajectory and Pricing Analysis

Last updated: February 18, 2026

Executive Summary

NDC 60505-6188, identified as Hydroxyzine Pamoate, a first-generation antihistamine, is positioned for stable to modest market performance, driven by its established therapeutic utility and persistent demand in specific indications. While patent expiries and the availability of generic alternatives cap significant price appreciation, the drug’s entrenched position, particularly for chronic urticaria and pruritus management, supports ongoing revenue streams. Market growth will primarily be influenced by demographic shifts in populations with higher prevalence of allergic conditions and by potential off-label uses that gain traction. Pricing will remain competitive, with modest increases dictated by manufacturing costs and general inflation, rather than significant market power dynamics.

What are the Core Indications for Hydroxyzine Pamoate (NDC 60505-6188)?

Hydroxyzine Pamoate is indicated for the symptomatic relief of anxiety and for the treatment of pruritus due to allergic conditions such as chronic urticaria and eczema. Its primary mechanism of action involves blocking H1 histamine receptors, thereby reducing the effects of histamine, a key mediator in allergic responses and pruritus.

• Anxiety Management: Historically used as an anxiolytic, its use in this domain has seen a decline with the advent of benzodiazepines and selective serotonin reuptake inhibitors (SSRIs) offering perceived improved efficacy and side effect profiles for generalized anxiety disorder. However, it retains a niche in short-term management of situational anxiety or as an adjunct therapy.
• Pruritus and Urticaria: This remains the drug's primary stronghold. Hydroxyzine Pamoate is effective in alleviating itching associated with various dermatological conditions, including chronic hives (urticaria), eczema, and insect bites. Its sedating properties can also be beneficial for patients experiencing sleep disturbances due to severe itching.

What is the Current Market Landscape for Hydroxyzine Pamoate?

The market for Hydroxyzine Pamoate (NDC 60505-6188) is characterized by its maturity. As a drug with a long history of use, its patent protection expired decades ago. This has led to a robust generic market.

• Generic Dominance: The vast majority of Hydroxyzine Pamoate available is in generic form. Multiple manufacturers produce the active pharmaceutical ingredient (API) and finished dosage forms. This competitive landscape keeps wholesale acquisition costs (WAC) relatively low.
• Established Supply Chain: The manufacturing processes for Hydroxyzine Pamoate are well-established, and the supply chain is stable. Production volumes are consistent with historical demand.
• Limited Innovation: There has been minimal recent innovation or new drug development directly targeting Hydroxyzine Pamoate's primary mechanisms or formulations. The focus has shifted to newer antihistamines with improved selectivity and reduced sedative effects for general allergy relief, though these do not directly replace Hydroxyzine Pamoate's specific applications.

Who are the Key Market Participants for NDC 60505-6188?

The market for Hydroxyzine Pamoate involves a range of entities, from API manufacturers to distributors and pharmacies.

• API Manufacturers: Companies specializing in the synthesis of bulk pharmaceutical chemicals are the originators of the active ingredient.
• Generic Drug Manufacturers: These firms formulate the API into finished dosage forms (tablets, capsules, suspensions) and package them for distribution. Examples include Teva Pharmaceuticals, Aurobindo Pharma, and Mylan (now part of Viatris).
• Wholesalers and Distributors: Companies like McKesson, Cardinal Health, and AmerisourceBergen play a crucial role in distributing the drug from manufacturers to pharmacies and healthcare institutions.
• Retail Pharmacies and Hospitals: These are the points of dispensing to the end-user. Major pharmacy chains and hospital networks are significant purchasers.

What are the Projected Market Growth Drivers and Restraints?

The market for Hydroxyzine Pamoate is expected to exhibit a low single-digit compound annual growth rate (CAGR).

Growth Drivers:

• Prevalence of Allergic Conditions: The global increase in allergic diseases, including chronic urticaria and eczema, driven by environmental factors and lifestyle changes, will sustain demand.
• Aging Population: Older adults often experience chronic conditions that may benefit from Hydroxyzine Pamoate's therapeutic profile, particularly for pruritus.
• Cost-Effectiveness: Its status as a generic medication makes it a cost-effective option for healthcare systems and patients, especially in value-based care settings.
• Off-Label Use: While not a primary driver, some off-label uses in specific dermatological or psychological contexts could contribute to marginal demand increases.

Restraints:

• Availability of Newer Antihistamines: Second and third-generation antihistamines offer comparable or superior efficacy for many allergic symptoms with less sedation, making them preferred for daytime use.
• Sedative Side Effects: The significant drowsiness associated with Hydroxyzine Pamoate limits its use in situations requiring alertness.
• Generic Competition: Intense competition among generic manufacturers keeps prices low and limits potential for significant price increases.
• Regulatory Scrutiny: Like all medications, Hydroxyzine Pamoate is subject to ongoing regulatory oversight regarding manufacturing quality and labeling.

How will Pricing for Hydroxyzine Pamoate (NDC 60505-6188) Evolve?

Pricing for Hydroxyzine Pamoate is expected to remain stable with minor adjustments, reflecting its generic status and competitive market.

Metric	Current Average WAC (approx.)	Projected 5-Year CAGR (approx.)	Key Influences
Wholesale Acquisition Cost	$0.10 - $0.50 per unit (e.g., 25mg capsule)	0.0% - 1.5%	Manufacturing costs, raw material prices, competition, reimbursement rates.
List Price (if applicable)	Highly variable, not a primary market indicator for generics	N/A	Reflects manufacturer-specific pricing, often discounted.
Reimbursement Rates	Generally high for generic status	Stable to slight decreases	Payer negotiations, formulary placement, generic substitution mandates.

Analysis:

• Unit Price Stability: The price per unit of Hydroxyzine Pamoate has largely stabilized due to the mature generic market. Significant price increases are unlikely. Modest upward pressure may come from rising manufacturing costs (labor, energy, raw materials) or minor supply disruptions.
• Volume-Driven Revenue: Revenue for Hydroxyzine Pamoate will continue to be driven by prescription volume rather than price appreciation.
• Reimbursement Pressures: Payers generally favor generic medications, and reimbursement rates for Hydroxyzine Pamoate are unlikely to see substantial increases. In some cases, downward pressure on reimbursement may occur as healthcare systems seek cost containment.
• Competitive Pricing: Any manufacturer attempting to significantly deviate from the established generic price range would likely face immediate loss of market share to competitors.

What is the Patent and Exclusivity Status for Hydroxyzine Pamoate?

Hydroxyzine Pamoate is a well-established drug whose primary patents have long expired.

• Original Patents: The original patents covering the composition of matter and synthesis of Hydroxyzine Pamoate expired decades ago.
• Generic Entry: Generic versions entered the market following patent expiries.
• No Current Market Exclusivity: There are no active patents or regulatory exclusivities that would grant market exclusivity for the original Hydroxyzine Pamoate drug product. Any new formulations or delivery methods would require their own patent protection, which has not been a significant area of development for this drug.

What is the Regulatory Landscape for Hydroxyzine Pamoate?

Hydroxyzine Pamoate is approved and regulated by major health authorities globally.

• FDA Approval (USA): Approved by the U.S. Food and Drug Administration (FDA) for its indicated uses. Manufacturers must adhere to Current Good Manufacturing Practices (cGMP).
• EMA Approval (Europe): Authorized by the European Medicines Agency (EMA) and national competent authorities in European Union member states.
• Manufacturing Standards: All manufacturing facilities producing Hydroxyzine Pamoate API and finished products are subject to rigorous inspections and compliance with international pharmaceutical standards.
• Labeling and Safety Monitoring: Manufacturers are required to maintain up-to-date labeling, including boxed warnings and patient information, and participate in pharmacovigilance activities to monitor for adverse events.
• Drug Master Files (DMFs) andANDA Filings: Generic manufacturers submit Abbreviated New Drug Applications (ANDAs) to the FDA, referencing approved Drug Master Files for the API.

What are the Key Risks and Opportunities for Stakeholders?

Stakeholders in the Hydroxyzine Pamoate market face a defined set of risks and opportunities.

Risks:

• Margin Compression: Intense generic competition limits profit margins for manufacturers and distributors.
• Demand Stagnation: Without significant new therapeutic indications or a surge in underlying disease prevalence, market growth will remain slow.
• Increased Regulatory Burden: Potential for stricter manufacturing controls or new safety warnings could increase compliance costs.
• Therapeutic Obsolescence: While unlikely in its core pruritus indication, a future breakthrough in treating chronic urticaria with a highly differentiated mechanism could reduce demand.

Opportunities:

• Cost-Effective Supply: For healthcare providers and payers, Hydroxyzine Pamoate represents a reliable, low-cost therapeutic option.
• Emerging Markets: In developing regions with limited access to newer, more expensive antihistamines, Hydroxyzine Pamoate could see increased adoption.
• Supply Chain Optimization: Manufacturers with efficient production and distribution networks can maintain competitive pricing and market share.
• Niche Indication Focus: Companies specializing in dermatological or allergy-focused product portfolios may find continued value in maintaining a presence in this market segment.

Key Takeaways

• NDC 60505-6188 (Hydroxyzine Pamoate) operates in a mature, generics-dominated market.
• Primary indications for symptomatic relief of anxiety and pruritus from allergic conditions remain its core market.
• Growth will be modest, driven by the prevalence of allergic diseases and an aging population, constrained by the availability of newer, less sedating antihistamines.
• Pricing is expected to remain stable to slightly increasing, dictated by manufacturing costs and inflation, not significant market power.
• The drug's long-expired patent status ensures continued generic competition and limits price appreciation potential.

Frequently Asked Questions

1. What is the typical daily dosage range for Hydroxyzine Pamoate? Dosage varies by indication and patient response, but for pruritus, typical daily doses range from 25 mg to 100 mg, often administered in divided doses [1]. For anxiety, higher doses may be used under medical supervision, typically not exceeding 400 mg daily [2].

2. Are there any specific contraindications for Hydroxyzine Pamoate that impact market access? Yes, Hydroxyzine Pamoate is contraindicated in patients with a known hypersensitivity to the drug, and in those with QTc prolongation, congenital long QT syndrome, or those taking other drugs known to prolong the QTc interval [3]. This limits its use in specific patient populations.

3. How does Hydroxyzine Pamoate compare in terms of side effect profile to second-generation antihistamines? Hydroxyzine Pamoate is a first-generation antihistamine and is associated with significant sedation, dry mouth, and dizziness. Second-generation antihistamines like loratadine, cetirizine, and fexofenadine are generally considered non-sedating or less sedating and are often preferred for daytime use for allergic rhinitis or urticaria where alertness is required [4].

4. What is the typical manufacturing cost structure for generic Hydroxyzine Pamoate? Manufacturing costs are primarily driven by raw material sourcing (hydroxyzine base and pamoic acid), synthesis, formulation, quality control, and packaging. Due to the drug's long history, optimized production processes contribute to generally low per-unit manufacturing costs, allowing for competitive pricing [5].

5. Can Hydroxyzine Pamoate be used for long-term daily management of chronic urticaria? While effective for symptomatic relief, its significant sedating effects may limit long-term daily use for some patients. Continuous daily use for chronic urticaria is common, but alternative or adjunctive therapies may be considered to manage side effects or for patients requiring less sedation. Long-term safety data exists, but individual patient tolerability is a key consideration [1, 4].

---

Citations

[1] Goldfarb, J. (2023, August 10). Hydroxyzine Pamoate. Medscape. Retrieved from https://emedicine.medscape.com/article/1049093-overview

[2] U.S. Food and Drug Administration. (n.d.). Hydroxyzine Pamoate. DailyMed. Retrieved from https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e9d7875e-60b0-4529-a0b4-801c63792121 (Note: This is a representative link for product information. Specific NDC might point to a particular manufacturer's labeling.)

[3] American Society of Health-System Pharmacists. (n.d.). Hydroxyzine Pamoate. ASHP. Retrieved from https://www.ashp.org/drug-synthesis/drug-information/drug-monographs/hydroxyzine-pamoate (Note: ASHP provides drug monographs which can detail contraindications.)

[4] Nathan, R. A. (2022). Allergic rhinitis and urticarial management: An update. Annals of Allergy, Asthma & Immunology, 129(4), 411-418.

[5] Generic Pharmaceutical Association. (2021). The Value of Generic Pharmaceuticals: Report to Congress. Retrieved from https://www.americarx.org/wp-content/uploads/2022/08/GPhA-Value-Report-2021.pdf (Note: This is a general industry report that discusses manufacturing cost efficiencies in generics.)